^
Association details:
| Biomarker: | KRAS G12R |
|---|---|
| Cancer: | Pancreatic Cancer |
| Drug: | Cotellic (cobimetinib) (MEK1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Cobimetinib plus gemcitabine is an active combination in KRAS G12R-mutated in previously chemotherapy-treated and failed pancreatic patients.
Published date:
05/13/2020
Excerpt:
Patients were divided into two groups; Group 1 consists of seven patients that were KRAS G12D/G12V mutated...In Group 2, one achieved PR and others stable disease. Median progression-free survival was 6.0 months (95% CI 3-9.3 months) and median OS has not been reached....Pancreatic cancer patients that demonstrate KRAS G12R mutations are treatable with a new active combination chemotherapy.
Secondary therapy:
gemcitabine
DOI:
10.1200/JCO.2020.38.15_suppl.4642
